TY - JOUR
T1 - Clinically relevant concentrations of bupivacaine inhibit rat aortic baroreceptors
AU - Chang, K. S.K.
AU - Yang, M.
AU - Andresen, M. C.
PY - 1994
Y1 - 1994
N2 - Bupivacaine is clinically associated with cardiovascular toxicity. To examine the possible role of drug actions at arterial baroreceptors, we studied discharge properties of baroreceptors in an in vitro aortic nerve- aortic arch preparation from rats. We measured single fiber discharge, pressure, and aortic diameter simultaneously during perfusion of the aortic arch with bupivacaine. Perfusion mean arterial pressure was held at 80 mm Hg. Only regularly discharging, presumably myelinated, baroreceptors were studied. To assess pressure threshold, threshold frequency, and maximum discharge rate, nerve activity was evoked by slow ramps of increasing pressure (<2 mm Hg/s) beginning at 20 mm Hg and ranging up to 150-170 mm Hg. Following replicate control measurements, test ramps were repeated in the presence of sodium nitroprusside (1 μM) and phentolamine (1 μM) to eliminate potential smooth muscle and α1-adrenoceptor effects, respectively. Bupivacaine was then added to the perfusate in increasing concentrations from 0.1 to 50 μM for 15 min to construct a full concentration-response curve at each level. Individual baroreceptors showed substantial depression of maximum discharge frequency and/or increases in pressure threshold at 1-5 μM bupivacaine. In overall population averages (n = 7), 5-10 μM bupivacaine clearly reduced maximum discharge and shifted the pressure threshold to higher values (P < 0.01). The net result was a general depression of discharge. Concentrations as low as 10 μM bupivacaine completely blocked discharge in some baroreceptors. Inasmuch as the pressure- diameter relations were not changed, discharge relations plotted against diameter showed equivalent changes. Bupivacaine-free solution reversed the block in all cases. Our results suggest that arterial baroreceptors are substantially-to-completely blocked in the range of bupivacaine concentrations encountered during clinical crises and thus this action may contribute to the early cardiovascular sequelae observed.
AB - Bupivacaine is clinically associated with cardiovascular toxicity. To examine the possible role of drug actions at arterial baroreceptors, we studied discharge properties of baroreceptors in an in vitro aortic nerve- aortic arch preparation from rats. We measured single fiber discharge, pressure, and aortic diameter simultaneously during perfusion of the aortic arch with bupivacaine. Perfusion mean arterial pressure was held at 80 mm Hg. Only regularly discharging, presumably myelinated, baroreceptors were studied. To assess pressure threshold, threshold frequency, and maximum discharge rate, nerve activity was evoked by slow ramps of increasing pressure (<2 mm Hg/s) beginning at 20 mm Hg and ranging up to 150-170 mm Hg. Following replicate control measurements, test ramps were repeated in the presence of sodium nitroprusside (1 μM) and phentolamine (1 μM) to eliminate potential smooth muscle and α1-adrenoceptor effects, respectively. Bupivacaine was then added to the perfusate in increasing concentrations from 0.1 to 50 μM for 15 min to construct a full concentration-response curve at each level. Individual baroreceptors showed substantial depression of maximum discharge frequency and/or increases in pressure threshold at 1-5 μM bupivacaine. In overall population averages (n = 7), 5-10 μM bupivacaine clearly reduced maximum discharge and shifted the pressure threshold to higher values (P < 0.01). The net result was a general depression of discharge. Concentrations as low as 10 μM bupivacaine completely blocked discharge in some baroreceptors. Inasmuch as the pressure- diameter relations were not changed, discharge relations plotted against diameter showed equivalent changes. Bupivacaine-free solution reversed the block in all cases. Our results suggest that arterial baroreceptors are substantially-to-completely blocked in the range of bupivacaine concentrations encountered during clinical crises and thus this action may contribute to the early cardiovascular sequelae observed.
UR - http://www.scopus.com/inward/record.url?scp=0028354192&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0028354192&partnerID=8YFLogxK
U2 - 10.1213/00000539-199403000-00015
DO - 10.1213/00000539-199403000-00015
M3 - Article
C2 - 8109768
AN - SCOPUS:0028354192
SN - 0003-2999
VL - 78
SP - 501
EP - 506
JO - Anesthesia and Analgesia
JF - Anesthesia and Analgesia
IS - 3
ER -